Pharmacotherapy of Psychiatric and Associated Comorbid Medical Conditions

October 27-28, 2012
Hilo, on the Big Island of Hawaii

Continuing Education Program

- Accredited for CME, CPE & AANP CE
Edward Fisher, Ph.D., R.Ph.
Associate Dean for Academic Affairs
Professor of Pharmacology & Toxicology
Director of the Masters of Science in Psychopharmacology Program
Director of the Doctorate in Pharmaceutical Science Program
University of Hawaii Hilo College of Pharmacy

Benjamin Chavez, Pharm.D.
Assistant Professor of Pharmacy Practice
University of Hawaii Hilo College of Pharmacy

Candace Tan, Pharm.D.
Assistant Professor of Pharmacy Practice
University of Hawaii Hilo College of Pharmacy
<table>
<thead>
<tr>
<th>DATE</th>
<th>TOPICS</th>
<th>TIME</th>
<th>SPEAKER(S)</th>
<th>HOURS of CE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, October 27, 2012</td>
<td>Schizophrenia, Eating Disorders &amp; Alzheimer’s Disease</td>
<td>Registration: 10:30- 11 am</td>
<td>Dr. Edward Fisher</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CE Program: 11 am - 1 pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lunch: 1 - 2 pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CE Program: 2- 4 pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Break: 4- 4:10 pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CE Program: 4:10- 6:10 pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, October 28, 2012</td>
<td>Depression, Anxiety, ADHD &amp; Metabolic Syndrome</td>
<td>Registration: 6:50- 7:10 am</td>
<td>Dr. Benjamin Chavez</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CE Program: 7:10- 9:10 am</td>
<td>Dr. Candace Tan</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Break: 9:10- 9:20 am</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CE Program: 9:20- 11:20 am</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lunch: 11:20 am– 12:20 pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CE Program: 12:20 pm- 2:50 pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Break: 2:50- 3:00 pm</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CE Program: 3- 5:30 pm</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CLICK HERE TO REGISTER NOW!
Upon completion of this activity, participants should be better able to:

* Describe the typical course of the disease processes associated with schizophrenia
* Recall the diagnostic criteria used for schizophrenia
* Describe the various subtypes of schizophrenia
* Describe the various clinical symptoms associated with the disease state
* Describe the prognosis and epidemiology of the disease state
* Explain the current theories on the etiology of the disease state
* Implement the current medical treatment for schizophrenia
* Recall the pharmacological properties of the drugs used to treat schizophrenia
* Compare and contrast the efficacy of drugs currently used to treat schizophrenia
* List the adverse effects associated with the drugs commonly used to treat schizophrenia
* Recall the diagnostic criteria used for various eating disorders
* Differentiate the accepted sub-types of eating disorders
* Describe the various clinical symptoms associated with various eating disorders
* Describe the prognosis and epidemiology of various eating disorders
* Explain the current theories on the etiology of various eating disorders
* Implement the current appropriate pharmacological treatment for various eating disorders
* Recall the pharmacological properties of the drugs used to treat eating disorders
* Compare and contrast the efficacy of drugs currently used to treat eating disorders
* List the adverse effects associated with the drugs commonly used to treat eating disorders
* Recall the diagnostic criteria used for Alzheimer’s disease
* Explain the current theories on the etiology of Alzheimer’s disease
* Describe the typical course of the disease processes and the stages of cognitive decline associated with Alzheimer’s disease
* Describe the various clinical symptoms associated with Alzheimer’s disease
* Discuss the prognosis and epidemiology of Alzheimer’s disease
* Implement appropriate pharmacotherapy for Alzheimer’s disease
* Recall the pharmacological properties of the drugs used to treat Alzheimer’s disease
* Compare and contrast the efficacy of the drugs used to treat Alzheimer’s disease
* List the adverse effects associated with the drugs commonly used to treat Alzheimer’s disease
LEARNING OBJECTIVES- October 28, 2012

* Upon completion of this activity, participants should be better able to:
* List the presenting symptoms, and DSM-IV criteria, of major depressive disorder
* Describe the treatment options available for depression, including, doses, routes of administration, advantages and disadvantages of each, drug-drug interactions, contraindications, and side effect profile
* Evaluate a patient with depression, provide basic counseling, and recommend appropriate drug therapy
* Counsel a parent of a child receiving antidepressants (i.e. warning signs, benefits vs. risks)
* State the possible theories behind increased suicidality in children receiving antidepressants
* Identify the common signs and symptoms of the different classes anxiety disorders
* Identify possible causes of anxiety disorders, including medical illnesses and medications
* Describe the treatment options available for the different anxiety disorders, including routes of administration, advantages and disadvantages of each, drug-drug interactions, and side effect profile
* Recommend appropriate treatment for a patient with an anxiety disorder
* Counsel a patient regarding their anxiety symptoms and medication
* Recognize the possible presentation of a patient with ADHD
* Describe the differences between the available stimulant formulations, including dosing schedule, tolerability, efficacy, and ease of use
* List the available non-stimulants for the treatment of ADHD and describe their role in treatment
* Formulate appropriate treatment and monitoring recommendations for a patient with ADHD
* Counsel and educate a patient with ADHD, and a parent of a patient with ADHD, regarding proper administration of stimulant and non-stimulant medications for ADHD
* Describe the goals of therapy for a patient with hypertension
* Recommend lifestyle changes for the management of hypertension
* Evaluate pharmacologic options available to treat hypertension, including advantages and disadvantages of each
* Describe evidence-based approaches to treat hypertension based on landmark clinical trials
* Design an appropriate treatment plan for a patient with hypertension
* Describe goals of therapy for a patient with diabetes
* Evaluate pharmacologic options available for diabetes, including advantages and disadvantages of each
* Develop an evidence-based treatment plan for a patient not meeting glycemic goals
* Effectively explain diabetes self-management education to a patient
* Describe treatment goals for a patient requiring lipid-lowering therapy
* Evaluate pharmacologic treatment options for dyslipidemia, including advantages and disadvantages of each
* Recommend an appropriate treatment plan for a patient with dyslipidemia
* Explain dyslipidemia treatment to a patient
The target audience is primary care providers, clinical pharmacists, APRN Rx, nurse practitioners, psychiatrists and other mental health professionals.

Disclosures:

Drs. Fisher, Chavez and Tan have no relationships to disclose. All other planning committee members and Continuing Education staff from the University of Hawaii Hilo College of Pharmacy have no relationships to disclose.

ACPE Accreditation Statement: October 27, 2012
The University of Hawaii Hilo College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based continuing education activity of University of Hawaii Hilo College of Pharmacy, an equal access/equal opportunity university (UAN: 0516-0000-12-003-L01-P). To receive the 6.0 contact hours of continuing education credit, pharmacists must attend the entire program and complete all registration and evaluations at its conclusion.

ACPE Accreditation Statement: October 28, 2012
The University of Hawaii Hilo College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is an application-based continuing education activity of University of Hawaii Hilo College of Pharmacy, an equal access/equal opportunity university (UAN: 0516-0000-12-004-L01-P). To receive the 9.0 contact hours of continuing education credit, pharmacists must attend the entire program and complete all registration and evaluations at its conclusion.

Physician Accreditation Statement:
The University of Hawaii Hilo College of Pharmacy is accredited by the Hawaii Medical Association to provide continuing medical education for physicians.
Credit Designation: October 27, 2012

*The University of Hawaii Hilo College of Pharmacy designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.*

Credit Designation: October 28, 2012

*The University of Hawaii Hilo College of Pharmacy designates this live activity for a maximum of 9.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.*

Hawaii Association of Professional Nurses (HAPN):

*Hawaii Association of Professional Nurses (HAPN) is a professional nursing association welcoming ALL Registered Nurses and nursing students in RN programs. We offer leadership and support on ALL professional nursing issues. HAPN is a group member of the American Academy of Nurse Practitioners (AANP), which represents the interests of the more than @ 135,000 US NPs. AANP accredits individual programs for continuing education and AANP-approved CE is universally accepted by all NP certifying bodies. This program is approved for 15.0 contact hours of continuing education (which includes 10.0 hours of Pharmacology) by the American Academy of Nurse Practitioners. Program ID 1207247. This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.*

CLICK HERE TO REGISTER NOW!

Questions? Please contact:
Amy Doff, CE Coordinator
doff@hawaii.edu
Phone: (808) 937-6456